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Cerenkov luminescence imaging (CLI) is a cost-eﬀective molecular imaging tool for biomedical applications of radiotracers. The
introduction of Cerenkov luminescence tomography (CLT) relative to planar CLI can be compared to the development of X-ray
CT based on radiography. With CLT, quantitative and localized analysis of a radiopharmaceutical distribution becomes feasible.
In this contribution, a feasibility study of in vivo radiopharmaceutical imaging in heterogeneous medium is presented. Coupled
with a multimodal in vivo imaging system, this CLT reconstruction method allows precise anatomical registration of the positron
probe in heterogeneous tissues and facilitates the more widespread application of radiotracers. Source distribution inside the small
animal is obtained from CLT reconstruction. The experimental results demonstrated that CLT can be employed as an available in
vivo tomographic imaging of charged particle emitters in a heterogeneous medium.
1.Introduction
Optical molecular imaging is a typical multidisciplinary
method promoted by biological, physical and chemical
sciences [1]. It is a powerful biomedical research tool [2]
with the advantage of having a low cost. However, there
are signiﬁcant challenges for commercialization of optical
imaging probes, especially for clinical studies [3]. To our
best knowledge, only one optical molecular imaging probe
approved by the US Food and Drug Administration (FDA),
indocyanine green(ICG),isusedinclinicalstudies.Recently,
ontheutilizationoftheVavilov-Cerenkoveﬀect,Liuetal.[4]
demonstrated the quantitative analysis of both radioactive
optical images and positron emission tomography (PET)
or single photon emission computed tomography (SPECT)
images of living subjects with a wide diversity of radioactive
probes.
Cerenkov luminescence is emitted from Cerenkov radia-
tion [5] during the initial decay process of medical isotopes.
These Cerenkov photons are detected with a low-noise
charge-coupled device (CCD) and converted into optical
images, which is Cerenkov luminescence imaging (CLI)
[6]. As an optical molecular imaging method, CLI can
quantitativelymap[7]thedistributionofradionuclides,such
as 18F, 131I, and 225Ac.
In order to obtain spatial and/or temporal localization
information of the radioactive source inside the medium,
Li et al. [8] proposed the corresponding Cerenkov lumi-
nescence tomography (CLT), assuming that the scattering
and absorption properties of tissues were homogeneous.
However, small animal inherently has optical heterogeneity
[9]. It is necessary to improve the physical model so as
to more accurately visualize the in vivo radioactive probe
distribution.
As for the meaning of optical coeﬃcients µa(r)a n dµs(r),
we can refer to the following deﬁnition [10]: µa(r)i sd e ﬁ n e d
as the probability of photon absorption in a medium per
unit path length, of which the reciprocal is referred to as the
mean absorption length; µs(r) is deﬁned as the probability
of photon scattering in a medium per unit path length, of
which the reciprocal is referred to as the scattering mean
free path. We usually describe the scattering property of
biological tissue as µ 
s(r) = (1−g)µs(r), which is the reduced
scattering coeﬃcient.2 International Journal of Biomedical Imaging
Our aim in this paper is to describe a feasibility
s t u d yf o rC L Ti nin vivo radiopharmaceutical imaging. The
mathematical model [10] of the proposed method is the
diﬀusion approximation. Although Lv et al. [11]e v a l u a t e d
the performance of the algorithm on the heterogeneous
phantom for bioluminescence tomography (BLT), its perfor-
mance in the inverse problem of CLT still requires further
study. The model-based iterative reconstruction is applied to
in vivo radioactive optical imaging in the paper. The results
of the physical experiments on nude mice demonstrated that
the proposed technique with ap r i o r istructural information
incorporated in the CLT inverse problem can improve the
quality of source reconstruction.
2. Methods
2.1. Diﬀusion Model. The in vivo Cerenkov light emission
spectrum [6] is quite wide (400–800nm) and overlaps with
the so-called near infrared window of biological tissues,
when light scattering dominates light absorption. This
photon propagation can be modelled by the steady-state
diﬀusion equation (DE) and Robin boundary condition
[12]. After a series of transformations, the matrix form of
DE on the discretized mesh with the permissible source
region strategy [13] can be obtained. It describes the linear
relationship between the boundary measured photon ﬂux
densityΦandtheunknownsourcedensityinthepermissible
source region S as follows:
AS = Φ,( 1 )
where A is a matrix generated from the DE model.
2.2. Image Reconstruction and Fusion. Because the inverse
problem is ill-posed for (1), we applied the method of
Tikhonov regularization. The reconstruction stability and
convergence were illustrated through numerical studies on
the heterogeneous phantom [11]. In the paper, the method
of the image fusion was published in Zhu’s Ph.D. thesis with
mathematical proof [14].
2.3. Materials and Instruments. The female Nu/Nu nude
mice used in the experiments were purchased from the
Department of Laboratory Animal Science, Peking Univer-
sity Health Science Centre. FDG was kindly provided by
the Department of Nuclear Medicine, Beijing Union Medical
College Hospital. Animal experimentation was conducted
under approved research protocols of the Animal Care and
Use Committee.
All imaging experiments were performed with an in
vivo molecular imaging system developed by our group, as
shown in Figure 1. The CCD camera (Princeton Instruments
VersArray 1300B, Roper Scientiﬁc, Trenton, NJ) has 1340 ×
1300 pixels with 20 × 20µm-sized pixels. The typical work
temperature of the CCD chip is −110◦C. Low readout and
binning noise makes this camera ideal for Cerenkov optical
imaging. The optical imaging system has a dark room that
can block both all external lights and internal high-energy
radiation. There is a local expansion and statistics algorithm
that can remove the noise of the Cerenkov optical images
prior to CLT reconstruction [15]. Meanwhile, the camera
was calibrated with an integrating sphere (USS-1200V-LL
Low-Light Uniform Source, Labsphere, North Sutton, NH).
The entire optical system was used for data acquisition
of Cerenkov luminescent images. The ﬁnal quantitative
calibration formula for the optical system is given by
S(r) =
2.09p
t
+1 0 .89

×10
−10W ·mm−2,( 2 )
where p is the CCD pixel intensity value and t is the
exposure time with s units. The Micro-CT system provided
3Danatomicalinformationinaccordancewithnormalusage
[16]. The small animal bed was marked with 24 simulta-
neously identiﬁable markers by the optical and Micro-CT
systems. System control and image processing were carried
out on a personal computer with Intel Core(TM)2 Duo
Processor 2.33GHz and 2GB RAM.
2.4. Radioactive Optical Imaging. In each experiment, we
needed to rotate the turntable 360 degrees to have access
to four luminescent images and the corresponding photo-
g r a p hi m a g e s( Figure 2). A CLI can be obtained after the
overlay process between the luminescence image and the
corresponding photograph image.
2.5. Structural and Optical Information Fusion. The dimen-
sion of the reconstructed Micro-CT data was 400 × 400 ×
560. The voxel size of the Micro-CT data was 0.15 ×
0.15 × 0.15mm. The Micro-CT data and four CLI images
were registered using ﬁxed markers. 3D Micro-CT data was
discredited into a tetrahedral mesh. 2D photos were then
mapped onto the surface of the mesh according to the
registration relation. The 3D ﬁnite element mesh with the
Cerenkov light intensity on the surface was the output of the
integration of structural and optical information.
2.6. Parameters of CLT Reconstruction. The entire ﬁnite
elementframeworkandtheTikhonovregularizationmethod
were implemented in C++ code. All of the parameters of
the ﬁnite element framework were the same as those used
in [11], except for the optical properties. The regularization
parameter was set to 0.01. In order to analyze the algorithm
more reasonably, the DisError is deﬁned as the distance error
of the distance between the actual source position and the
reconstructed source position by the L2 norm as follows:
DisError =  r1 −r2 
2,( 3 )
where r1 is the central coordinate of the reconstruction
source with maximum density and r2 is that of the actual
source center.
3. Results
A 21g mouse was anesthetized with 2% isoﬂurane delivered
in medical air. It was successively injected with 0.20ml of
Fenestra LC and 11.10MBq of 2 -deoxy-2 -[18F]ﬂuoro-D-
glucose (FDG) via the tail vein. The healthy mouse wasInternational Journal of Biomedical Imaging 3
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Figure 1: Schematic diagram of our imaging system. In vivo imaging system consists of a CCD camera, small animal anesthesia machine, a
Micro-focus X-ray source, an X-ray ﬂat panel detector, a rotation stage, and an antiradiation shield.
Camera
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Figure 2: System block diagram of the in vivo imaging system,
developed by ourselves. The region near the bladder belongs to the
view of the CCD camera.
intactlyaﬃxedonthesmallanimalbed,asshowninFigure 3.
After half an hour, the mouse was scanned by the Micro-CT
system, and the system independent parameters of power,
voltage, and exposure time were set at 50W, 50kVp, and
0.47s, respectively. After waiting for a quarter of an hour,
we used the camera to collect the Cerenkov luminescence
images with the aperture number f to 2.8, the binning value
equal to 2 and the integration time equal to 180s. There was
no optical ﬁlter, because the Cerenkov light signal was very
weak. A CLI was obtained after a 90-degree rotation of the
turntable, as shown in Figure 3.
Optical marker Micro-CT marker
Figure 3: The views of the mouse bed with the ﬁxed markers. The
healthymousewasinjectedwithFenestraLCandFDG.Therotation
stage is set to rotate at 0◦,9 0 ◦, 180◦, and 270◦ for taking photos
respectively. The CCD camera was ﬁxed in front of the mouse bed.
3.1. CLT Reconstruction. The designed CLT reconstruction
process with optical property priors is illustrated in Figure 4.
During the processing, there was a relatively concentrated
and strong Cerenkov light near the bladder region. The
geometric center (34.70mm, 14.49mm, 5.13mm) of the
bladder was chosen as the actual light center according to
the acquired Micro-CT information. Physically, the bladder
isﬁlledwithliquids.FDGuptakeanddistribution,asaliquid
in the bladder, should be homogeneous. We selected part of
the reconstructed Micro-CT data along the Z axis from the
65th to the 229th slice to reconstruct the source position.
The segmented Micro-CT data with the dimension equal
to 400 × 400 × 165 was discretized into 3555 points, 381154 International Journal of Biomedical Imaging
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Figure 4: Schematic of radioactive source distribution reconstruction with optical property heterogeneity. The mouse was scanned by our
multimodal molecular imaging system. 3D MicroCT data and planar optical images were collected by the same system. The interval degree
was 90 for multiangle imaging. 2D optical intensity distribution is mapped on the 3D surface in accordance with the registering relationship.
CLT is the output of the information fusion and optical tomography reconstruction.
Table 1: Optical parameters of the nude mouse [17], 10−2 mm−1.
Material µa(r) µ 
s(r)
Muscle 3.20 58.60
Kidneys 1.00 83.00
Bladder [18] 68.40 139.00
Bone 0.24 93.50
triangles and 18690 tetrahedrons. Figure 4 shows the surface
of tissues including muscle, kidneys, bladder, and bone. The
volume percentage of each tissue is 77.14% (muscle), 3.27%
(kidneys), 2.27% (bladder), and 17.32% (bone). The 2D
photos were then mapped onto the surface of the mesh. The
meshandCerenkovlightintensitydistributiononthesurface
were used for CLT reconstruction. The optical parameters
of the mouse [9] are shown in Table 1.H e r e ,µa(r)i s
the absorption coeﬃcient; µ 
s(r) is the reduced scattering
coeﬃcient. These were the weighted values because of the
mixed optical spectrum used in the experiment. According
to the surface light distribution (Figure 4), the permissible
source region was set as follows:
P =

r | 30 <x<40mm, 11 <y<20mm, 2 <z<8mm

.
(4)
Finally, we carried out the reconstruction. In theory,
it is an optimization problem to compute source distribu-
tion, which seeks a regularized diﬀerence minimizing the
observed boundary measurements of light distribution and
the boundary measurements predicted from a mathematical
model.
3.2. CLT with and without Optical Property Priors. The
proposed technique on a homogeneous model (HM) and
heterogeneous model (HR) were performed. In the HM
experiment, the optical property parameters of the mouse in
the diﬀusion model were set to µa(r) = 4.10 × 10
−2 mm and
µ 
s(r) = 67.27 ×10
−2 mm in terms of the volume percentage,
because there were no optical property priors. Matrix A
formed in the reconstruction procedure was 737 × 1371.
Next, we performed the CLT reconstruction with the optical
property priors. This was the HR experiment. We could
obtain two sets of the reconstructed results, as shown in
Figure 5. The center of the tetrahedron with the maximum
intensity was used as the reconstructed source center (RSC.).
The quantitative information of the results from both HM
and HR is summarized in Table 2. The reconstruction times
of the proposed method in the last reconstruction procedure
were only 0.30s. Based on the HR, the distance error was
only 1.41mm, but was 2.32mm in the HM after inverseInternational Journal of Biomedical Imaging 5
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Figure 5: Slices of the in vivo ﬂux density distribution through the reconstructed source center successively from XZ, YZ,a n dXY views.(a)
Three slices from 3D views in HM; (b) three slices from 3D views in HR. Peak values of the ﬂux densities in diﬀerent slices were normalized
to 1, in order to simultaneously demonstrate reconstructed source centers. The unit of the X, Y,a n dZ axes is in mm.
reconstruction. These results proved that optical property
heterogeneity can help CLT reconstruction.
4. Discussion and Conclusion
CLT simultaneously has the characteristics of radioisotope-
labeled molecules and optical imaging. Coupled with the
information on the anatomy of the small animal, the
reconstructeddistanceerrorwasreduced.Theseencouraging
results proved that optical property heterogeneity can help
CLT reconstruction. Furthermore, source depth and ﬂux
density distribution in the mouse were calculated by the rule
of CLT reconstruction. This paper proposed a theoretical
approach to the pharmacokinetic and dynamic imaging for
radioactive probes in diﬀerent tissues.
More research is needed to improve the spatial resolution
of the inverse source reconstruction. It is necessary to
further explore the laws of Cerenkov light propagation in
small living animals. This may give us a more practical
m a t h e m a t i c a lm o d e l ,s u c ha sm u l t i s p e c t r a lo p t i c s ,g e n e r a l
approximation, and whole body reconstruction. We should
improve the in vivo optical imaging system and explore
the best optimization time of the radioactive tracer drug
injection and image acquisition in order to adapt to a lower
dose of radioisotopes. The paradox is that we need to detect
enough light to carry out the CLT reconstruction. For a
tumor model, the speciﬁcity, dose of the radionuclide, and
the tumor cell characteristics will impact the minimum
concentration of the radiotracer for CLT reconstruction. In
Table 2: Comparison of CLT with and without optical property
priors.
Model HM. HR.
Maximum density
(10−10 W·mm−2) 12.84 12.98
RSC. (mm) (34.12, 15.67, 6.93) (34.12, 15.67, 6.93)
DisError (mm) 2.23 1.41
addition, the anatomical location and shape of tissues or
tumors to be recovered needs to be reconsidered, such as
determining their depth.
The linear relationship between Cerenkov optical images
and PET/SPECT images has been accepted as common
knowledge.Intheory,Cerenkovradiationisproducedduring
the initial decay process, and is thereby more localized
to the decay event than the annihilation event tracked by
PET/SPECT scanning. The Cerenkov radiation spectrum is
weighted toward the ultraviolet and blue bands. Optical
absorption and scattering will reduce the sensitivity of CLT.
However,oneadvantageofCLTisthatitisalowcostimaging
system and is known for its ease of operation.
In conclusion, the distribution of the radiopharmaceu-
tical inside the heterogeneous medium can be imaged by
usingtheproposedCLTtechniquewithoutPET/SPECT.This
will allow the spread of in vivo pharmacokinetic imaging
research with a certain radiotracer to laboratories with
limited budgets.6 International Journal of Biomedical Imaging
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